Prediction of response to acute neuroleptic treatment in schizophrenia.

Abstract:

:Predicting the outcome of treatment with neuroleptics and understanding the factors that contribute to variability in the response to these drugs have preoccupied researchers and clinicians since the class was developed. Clinicians need empirically based prospective criteria in order to choose a treatment strategy that will lead to the best response from the patient while minimizing side effects. Thus the optimal strategy will match patient, illness and drug characteristics. Before a response can be predicted, the researcher needs explicit concepts and definitions on the course of the illness, drug responses, treatment outcome and predictive criteria. Whereas outcome refers to an arbitrary endpoint of an illness, whether spontaneous or modified by treatment, response is a treatment-related concept. Response refers to a change in the course of the illness which is defined either by pre- or post-treatment criteria and is caused by treatment. Apart from treatment, the spontaneous course of the illness is shaped and modified by various factors, which are referred to as potential outcome/response predictors sampled from a wide area of patient, illness and environmental characteristics. A superordinate concept of prediction must show how these potential determinants of (treatment) course and outcome relate to each other in biopsychosocial terms. Valid predictions of response can only be expected if recognizable rules are operative in the illness course and the treatment outcome. With increasing knowledge about the pathophysiology of the illness, its course and potential determinants, the development of valid predictive algorithms will be promoted. The application of vigorous research strategies in future pharmacological treatment studies will also be required to reach this goal.

authors

Gaebel W

doi

10.1097/00004850-199605002-00008

subject

Has Abstract

pub_date

1996-05-01 00:00:00

pages

47-54

eissn

0268-1315

issn

1473-5857

journal_volume

11 Suppl 2

pub_type

杂志文章,评审
  • Theory and practice in the management of depressive disorders.

    abstract::Scientific, professional, and governmental bodies have in recent years intensified efforts to formulate guidelines for the treatment of depression with the goal that medical practice should comply with these standards and thus improve patient care. 'Evidence-based medicine' demands that medical practice should explici...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199906003-00004

    authors: Linden M

    更新日期:1999-06-01 00:00:00

  • Concomitant use of lamotrigine and aripiprazole increases risk of Stevens-Johnson syndrome?

    abstract::Stevens-Johnson syndrome is a severe and potentially life-threatening cutaneous reaction associated with lamotrigine. The incidence of developing Stevens-Johnson syndrome during lamotrigine therapy is low. On the basis of the glutamate and dopamine neuron dysregulation hypothesis in schizophrenia, we propose new strat...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000224789.21406.81

    authors: Shen YC,Chen SJ,Lin CC,Chen CH

    更新日期:2007-07-01 00:00:00

  • Can severe cardiorespiratory dysregulation induced by clozapine monotherapy be predicted?

    abstract::Severe orthostatic and cardiorespiratory dysregulation may occur during institution of clozapine therapy both during concomitant benzodiazepine medication and on reinstitution of clozapine after a washout period. Extensive medical and neurological workup before and after the trials can nevertheless be normal. The abse...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199300830-00012

    authors: Bredbacka PE,Paukkala E,Kinnunen E,Koponen H

    更新日期:1993-10-01 00:00:00

  • Resurrecting the discussion on neurotoxicity of lithium at therapeutic levels.

    abstract::Lithium is widely used in the treatment of bipolar disorder. Here we describe the syndrome of irreversible lithium-effectuated neurotoxicity in a patient within therapeutic doses and levels, which persisted after discontinuation of Lithium. A 50-year-old gentleman with Bipolar disorder presented with symptoms of Mania...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000341

    authors: Jha A,Pai NM,Ganjekar S,Desai G,Chaturvedi SK

    更新日期:2021-03-01 00:00:00

  • Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients.

    abstract::Treatments given to patients with primary psychotic disorders include mood stabilizers (MSs) combined with other psychotropics, despite the limited evidence of efficacy, safety, and lack of regulatory approval. We analyzed records of 636 inpatients at the McLean Hospital (2002-2009), who were diagnosed with bipolar di...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e328340c0de

    authors: Ventriglio A,Vincenti A,Centorrino F,Talamo A,Fitzmaurice G,Baldessarini RJ

    更新日期:2011-03-01 00:00:00

  • The effect of fluoxetine on sleep: a longitudinal, double-blind polysomnographic study of healthy volunteers.

    abstract::Fluoxetine, a selective inhibitor of serotonin (5-HT) uptake, was compared with placebo in a randomized double-blind longitudinal trial in 12 healthy volunteers. Sleep polygraphic recordings were performed at home twice before and once after 6 days of medication. After 6 days fluoxetine significantly decreased the amo...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199409000-00009

    authors: Vasar V,Appelberg B,Rimón R,Selvaratnam J

    更新日期:1994-09-01 00:00:00

  • The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder.

    abstract::The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. T...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/YIC.0000000000000175

    authors: Golubchik P,Rapaport M,Weizman A

    更新日期:2017-09-01 00:00:00

  • Quetiapine-induced myoclonus.

    abstract::We report a case of myoclonus induced by quetiapine. A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effe...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200503000-00011

    authors: Velayudhan L,Kirchner V

    更新日期:2005-03-01 00:00:00

  • Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.

    abstract::The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia. In this double-blind, placebo-controlled study the dose of each drug was incre...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-199707000-00003

    authors: Hayashi T,Yokota N,Takahashi T,Tawara Y,Nishikawa T,Yano T,Furutani M,Fujikawa T,Horiguchi J,Yamawaki S

    更新日期:1997-07-01 00:00:00

  • Clozapine-associated neutropenia in Latin America: incidence report of 5380 Chilean users.

    abstract::Systematic information about Latino clozapine users is still scarce. Our aim was to evaluate the risk of clozapine-associated neutropenia in a Chilean cohort using the last Food and Drug Administration's recommendations for clozapine monitoring. Findings should improve clinical practice and promote changes in clozapin...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000270

    authors: Mena CI,Nachar RA,Crossley NA,González-Valderrama AA

    更新日期:2019-09-01 00:00:00

  • Depression in the community: results of the first Italian survey.

    abstract::The 6-month prevalence of depression in the Italian community was evaluated by means of the modified-Mini-International-Neuropsychiatric Interview (MINI) administered with a computer-prompted interview to a representative panel of 3550 individuals. Major depression and minor depression accounted for 8.0% and 2.9% of t...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200101000-00006

    authors: Dubini A,Mannheimer R,Pancheri P

    更新日期:2001-01-01 00:00:00

  • A novel approach to rater training and certification in multinational trials.

    abstract::Clinical trials are becoming increasingly international in scope. Global studies pose unique challenges in training and calibrating raters owing to language and cultural differences. Recent findings that poorly conducted interviews reduce study power, makes attention to raters' clinical skills critical. In this study,...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3280803dad

    authors: Jeglic E,Kobak KA,Engelhardt N,Williams JB,Lipsitz JD,Salvucci D,Bryson H,Bellew K

    更新日期:2007-07-01 00:00:00

  • Continuity of treatment with benzodiazepines in dementia patients: an analysis of German health insurance claims data.

    abstract::Long-term treatment with benzodiazepines (BZD) should be avoided in dementia patients because of an increased risk of adverse events. We evaluated how continuously dementia patients were prescribed BZD over 12 months. For this observational study, we used claims data from a large German public sickness fund for 2014 a...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000230

    authors: Hessmann P,Jan Zeidler,Neubauer S,Abdel-Hamid M,Stahmeyer J,Eberhard S,Wolff-Menzler C,Wiltfang J,Kis B

    更新日期:2018-09-01 00:00:00

  • Risperidone-induced retrograde ejaculation: case report and review of the literature.

    abstract::Medication adherence with antipsychotics is adversely impacted by the burden of untoward adverse effects. In particular, sexual side-effects may interfere with compliance, but are often underreported by patients. Sexual dysfunction related to hyperprolactinemia is commonly described, but ejaculatory disturbance due to...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200403000-00009

    authors: Loh C,Leckband SG,Meyer JM,Turner E

    更新日期:2004-03-01 00:00:00

  • Antidepressant-induced hypomania in obsessive-compulsive disorder.

    abstract::Out of ten consecutive patients with DSM-III-R obsessive-compulsive disorder without any previous history of bipolarity, three patients showed antidepressant-induced hypomania (clomipramine, one patient; fluvoxamine, two patients) within the first 5 to 8 weeks of the drug treatment. These data support the previous res...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199609000-00008

    authors: Rihmer Z,Barsi J,Belsõ N,Pestality P,György S

    更新日期:1996-09-01 00:00:00

  • Iloperidone-induced retrograde ejaculation.

    abstract::This case series describes the development of retrograde ejaculation with the antipsychotic iloperidone. Iloperidone is a relatively new antipsychotic and has a strong α-1 receptor antagonism, which may explain this rare adverse effect. ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e32835e9112

    authors: Freeman SA

    更新日期:2013-05-01 00:00:00

  • Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients.

    abstract::The introduction of second generation antipsychotics (SGA) represents a major advance in the treatment of schizophrenia. Concerns about the metabolic and cardiovascular adverse effects of the SGA have been widely disseminated. The benefits and risks of these drugs have been studied with a focus on particular organ sys...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200511000-00006

    authors: Barak Y,Swartz M,Plopsky I

    更新日期:2005-11-01 00:00:00

  • Antidepressant interactions with warfarin.

    abstract::The interactions between warfarin and antidepressants can have potentially serious consequences resulting from enhanced or reduced anticoagulant activity. Information about such interactions was obtained from a Medline and hand search of the published literature, and by directly contacting manufacturers. The different...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199803000-00006

    authors: Duncan D,Sayal K,McConnell H,Taylor D

    更新日期:1998-03-01 00:00:00

  • High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia.

    abstract::Several cardiovascular risk factors have been linked to antipsychotic treatment and cardiovascular mortality is increased in these patients compared to the general population. The full metabolic syndrome (or its components) is associated with an increased risk of cardiovascular disorders. The prevalence of the metabol...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000188215.84784.17

    authors: Hägg S,Lindblom Y,Mjörndal T,Adolfsson R

    更新日期:2006-03-01 00:00:00

  • Tardive dyskinesia in bipolar affective disorder: a catchment area study.

    abstract::The prevalence of tardive dyskinesia in a consecutive series of 69 patients with bipolar affective disorder admitted to a catchment area service was found to be 19%. Prevalence increased with age and was related to the age of onset of bipolar disorder and number of previous episodes. Patients with tardive dyskinesia w...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199100610-00006

    authors: Hunt N,Silverstone T

    更新日期:1991-04-01 00:00:00

  • Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.

    abstract::Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment. At follow-up most patients (74%) did not suffer from panic attacks at all. In the beginnin...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199300820-00006

    authors: Lepola UM,Rimón RH,Riekkinen PJ

    更新日期:1993-07-01 00:00:00

  • The effects of moclobemide on psychomotor performance and cognitive function.

    abstract::Sixteen young male volunteers received single doses of moclobemide 200 mg, moclobemide 400 mg, amitriptyline 50 mg and placebo in a double-blind crossover study. Subjects then completed a test battery which is sensitive to the effects of psychoactive drugs at 1, 2, and 4 h post-dose. The test battery included tasks of...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199300810-00007

    authors: Fairweather DB,Kerr JS,Hindmarch I

    更新日期:1993-04-01 00:00:00

  • Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.

    abstract::The use of certain atypical antipsychotics has been associated with metabolic disturbances. We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine. Three hundred and seventy-seven adult patients with schizophrenia were randomized to eithe...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0b013e3280148c29

    authors: Peuskens J,De Hert M,Mortimer A,SOLIANOL Study Group.

    更新日期:2007-05-01 00:00:00

  • Treatment of generalized anxiety disorder with citalopram.

    abstract::Serotonin reuptake inhibitors (SSRI), such as venalafaxine and paroxetine, are used in the treatment of generalized anxiety disorder (GAD). Patients with GAD frequently have comorbid psychiatric disorders, such as depression. SSRIs are effective in the treatment of a variety of anxiety disorders and depression. Citalo...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200205000-00002

    authors: Varia I,Rauscher F

    更新日期:2002-05-01 00:00:00

  • Therapeutic receptor-blocking concentrations of neuroleptics.

    abstract::The therapeutic concentrations of antipsychotic drugs in the patient's plasma water or spinal fluid are identical to their blocking potencies in vitro at the dopamine D2 receptor, with the exception of clozapine which acts at D4. The variation in K values between laboratories stems from the fact that the apparent K va...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Seeman P

    更新日期:1995-09-01 00:00:00

  • Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials.

    abstract::Small studies have shown positive effects from adding a variety of antipsychotic agents in patients with obsessive-compulsive disorder who are unresponsive to treatment with serotonin reuptake inhibitors. The evidence, however, is contradictory. This paper reports a meta-analysis of existing double-blind randomized pl...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/01.yic.0000215083.57801.11

    authors: Fineberg NA,Stein DJ,Premkumar P,Carey P,Sivakumaran T,Vythilingum B,Seedat S,Westenberg H,Denys D

    更新日期:2006-11-01 00:00:00

  • Dose-dependent olanzapine-associated leukopenia: three case reports.

    abstract::Leukopenia and agranulocytosis are well reported and dangerous haematological side-effects associated with the use of typical and atypical antipsychotics. These potentially life-threatening phenomena have led to treatment discontinuation and the consequent reemergence of psychiatric symptoms. We report three cases of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200103000-00007

    authors: Kodesh A,Finkel B,Lerner AG,Kretzmer G,Sigal M

    更新日期:2001-03-01 00:00:00

  • DIABCARE Quality Network in Europe--a model for quality management in chronic diseases.

    abstract::The DIABCARE Q-Net project developed a complete and integrated information technology system to monitor diabetes care, according to the gold standards of the St Vincent Declaration Action Program. This is the first Telematic platform for standardized documentation on medical quality and evaluation across Europe, which...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200104003-00002

    authors: Piwernetz K

    更新日期:2001-04-01 00:00:00

  • Construction and validation of the My Medicines and Me Questionnaire for assessment of the self-reported side effects of psychotropic medication.

    abstract::We aimed to construct and assess the psychometric properties of the My Medicines and Me Questionnaire (M3Q), a self-report side-effect questionnaire for mental health patients. Thirty individuals taking a psychotropic medication completed the M3Q side-effect checklist along with the Liverpool University Neuroleptic Si...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000072

    authors: Ashoorian DM,Davidson RM,Rock DJ,Dragovic M,Clifford RM

    更新日期:2015-07-01 00:00:00

  • Carbamazepine in rapid cycling bipolar affective disorder.

    abstract::Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-198804000-00003

    authors: Joyce PR

    更新日期:1988-04-01 00:00:00